tetano
Editor, Senior Moderator
Open Microbiol J. 2017 Nov 30;11:316-329. doi: 10.2174/1874285801711010316. eCollection 2017.
[h=1]Live Attenuated Reassortant Vaccines Based on A/Leningrad/134/17/57 Master Donor Virus Against H5 Avian Influenza.[/h] Kiseleva I[SUP]1,[/SUP][SUP]2[/SUP], Larionova N[SUP]1[/SUP], Rudenko L[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]Background:[/h] The H5N1 avian influenza was first recognized in humans in Hong Kong 20 years ago. Current enzootic spread of highly pathogenic H5N1 virus among wild and domestic poultry and a number of severe human respiratory diseases caused by this pathogen have stimulated necessity of development of potentially pandemic influenza vaccines.
[h=4]Discussion:[/h] In the past few years, significant research was conducted on how to prevent H5N1 influenza. Live, attenuated cold-adapted reassortant influenza vaccine (LAIV) is considered as one of the most promising candidates for pandemic and prepandemic vaccines. LAIV has proven to be safe and efficacious; pandemic LAIV might be more effective than inactivated vaccine in providing broader immune response.
[h=4]Conclusion:[/h] This review covers development of LAIVs against potential avian "pandemic" H5N1 subtype based on cold-adapted A/Leningrad/134/17/57 (H2N2) master donor virus backbone, and their preclinical and clinical studies.
[h=4]KEYWORDS:[/h] Future pandemic; H2N2; Highly pathogenic H5N1 avian influenza; LAIV; Live attenuated pandemic influenza vaccine
PMID: 29290844 PMCID: PMC5737031 DOI: 10.2174/1874285801711010316
[h=1]Live Attenuated Reassortant Vaccines Based on A/Leningrad/134/17/57 Master Donor Virus Against H5 Avian Influenza.[/h] Kiseleva I[SUP]1,[/SUP][SUP]2[/SUP], Larionova N[SUP]1[/SUP], Rudenko L[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]Background:[/h] The H5N1 avian influenza was first recognized in humans in Hong Kong 20 years ago. Current enzootic spread of highly pathogenic H5N1 virus among wild and domestic poultry and a number of severe human respiratory diseases caused by this pathogen have stimulated necessity of development of potentially pandemic influenza vaccines.
[h=4]Discussion:[/h] In the past few years, significant research was conducted on how to prevent H5N1 influenza. Live, attenuated cold-adapted reassortant influenza vaccine (LAIV) is considered as one of the most promising candidates for pandemic and prepandemic vaccines. LAIV has proven to be safe and efficacious; pandemic LAIV might be more effective than inactivated vaccine in providing broader immune response.
[h=4]Conclusion:[/h] This review covers development of LAIVs against potential avian "pandemic" H5N1 subtype based on cold-adapted A/Leningrad/134/17/57 (H2N2) master donor virus backbone, and their preclinical and clinical studies.
[h=4]KEYWORDS:[/h] Future pandemic; H2N2; Highly pathogenic H5N1 avian influenza; LAIV; Live attenuated pandemic influenza vaccine
PMID: 29290844 PMCID: PMC5737031 DOI: 10.2174/1874285801711010316